Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cutia Therapeutics's Enterprise Value is HK$880.3 Mil.
Cutia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-2,143.0 Mil. Therefore, Cutia Therapeutics's EV-to-EBIT ratio for today is -0.41.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cutia Therapeutics's Enterprise Value is HK$880.3 Mil.
Cutia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-2,109.7 Mil. Therefore, Cutia Therapeutics's EV-to-EBITDA ratio for today is -0.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cutia Therapeutics's Enterprise Value is HK$880.3 Mil.
Cutia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$150.5 Mil. Therefore, Cutia Therapeutics's EV-to-Revenue ratio for today is 5.85.
Cutia Therapeutics Enterprise Value Historical Data
The historical data trend for Cutia Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cutia Therapeutics Enterprise Value Chart
Cutia Therapeutics Annual Data
Trend
Dec21
Dec22
Dec23
Enterprise Value
-
-
1,121.29
Cutia Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
Enterprise Value
-
-
-
6,047.77
2,230.90
Competitive Comparison of Cutia Therapeutics's Enterprise Value
For the Biotechnology subindustry, Cutia Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's Enterprise Value falls into.
Cutia Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cutia Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics (HKSE:02487) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cutia Therapeutics's current Enterprise Value is HK$880.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-2,143.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cutia Therapeutics's current Enterprise Value is HK$880.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-2,109.7 Mil.
Cutia Therapeutics's current Enterprise Value is HK$880.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$150.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cutia Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cutia Therapeutics (HKSE:02487) Business Description
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02487 has been successfully added to your